Avelumab plus sacituzumab govitecan versus avelumab monotherapy as first-line maintenance treatment in patients with advanced urothelial carcinoma: JAVELIN Bladder Medley interim analysis
Jean Hoffman‐Censits, Marinos Tsiatas, Peter Mu‐Hsin Chang, Minu Kim, L. Antonuzzo, Su‐Jin Shin, Georgios Gakis, Normand Blais, Sung Hoon Kim, Angela B. Smith, Jóse Ángel Arranz Arija, Yu‐Li Su, Flora Zagouri, M. Maruzzo, Christophe Tournigand, Frédéric Forget, A. Schneider, Karin Tyroller, N. Jacob, P. Grivas, Begoña P. Valderrama
Topics & Concepts
JavelinAvelumabMedicineUrothelial carcinomaInterim analysisInterimOncologyInternal medicineUrologyFirst line treatmentMetastatic Urothelial CarcinomaUrothelial cancerBladder cancerChemotherapyImmunotherapyCancerClinical trialPembrolizumabMechanical engineeringThrowingArchaeologyEngineeringHistoryBladder and Urothelial Cancer TreatmentsRenal cell carcinoma treatmentEsophageal Cancer Research and Treatment